214 related articles for article (PubMed ID: 3621160)
1. Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.
de Bruin PA; Griffioen G; Verspaget HW; Verheijen JH; Lamers CB
Cancer Res; 1987 Sep; 47(17):4654-7. PubMed ID: 3621160
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator profiles in neoplastic tissues of the human colon.
de Bruin PA; Griffioen G; Verspaget HW; Verheijen JH; Dooijewaard G; van den Ingh HF; Lamers CB
Cancer Res; 1988 Aug; 48(16):4520-4. PubMed ID: 3260815
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activators in human nasal polyps and mucosa.
Larsen K; de Maat MP; Jespersen J
Rhinology; 1997 Dec; 35(4):175-7. PubMed ID: 9532638
[TBL] [Abstract][Full Text] [Related]
4. Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.
Skelly MM; Troy A; Duffy MJ; Mulcahy HE; Duggan C; Connell TG; O'Donoghue DP; Sheahan K
Clin Cancer Res; 1997 Oct; 3(10):1837-40. PubMed ID: 9815571
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.
Ganesh S; Sier CF; Griffioen G; Vloedgraven HJ; de Boer A; Welvaart K; van de Velde CJ; van Krieken JH; Verheijen JH; Lamers CB
Cancer Res; 1994 Aug; 54(15):4065-71. PubMed ID: 8033138
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator content of human colon tumors and normal mucosae: separation of enzymes and partial purification.
Corasanti JG; Celik C; Camiolo SM; Mittelman A; Evers JL; Barbasch A; Hobika GH; Markus G
J Natl Cancer Inst; 1980 Aug; 65(2):345-51. PubMed ID: 6931252
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
Kirchheimer JC; Pflüger H; Ritschl P; Hienert G; Binder BR
Invasion Metastasis; 1985; 5(6):344-55. PubMed ID: 4066206
[TBL] [Abstract][Full Text] [Related]
8. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.
Sier CF; Verspaget HW; Griffioen G; Verheijen JH; Quax PH; Dooijewaard G; De Bruin PA; Lamers CB
Gastroenterology; 1991 Dec; 101(6):1522-8. PubMed ID: 1955118
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
Camiolo SM; Greco WR
Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
[TBL] [Abstract][Full Text] [Related]
10. Differential activation of total and EGF receptor (EGF-R) tyrosine kinase (tyr-k) in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer.
Malecka-Panas E; Kordek R; Biernat W; Tureaud J; Liberski PP; Majumdar AP
Hepatogastroenterology; 1997; 44(14):435-40. PubMed ID: 9164515
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activators in the intestine of patients with inflammatory bowel disease.
de Bruin PA; Crama-Bohbouth G; Verspaget HW; Verheijen JH; Dooijewaard G; Weterman IT; Lamers CB
Thromb Haemost; 1988 Oct; 60(2):262-6. PubMed ID: 3146142
[TBL] [Abstract][Full Text] [Related]
12. DNA in situ sensitivity to denaturation: a new parameter for flow cytometry of normal human colonic epithelium and colon carcinoma.
Kunicka JE; Darzynkiewicz Z; Melamed MR
Cancer Res; 1987 Aug; 47(15):3942-7. PubMed ID: 3607742
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-type plasminogen activator in colorectal carcinomas and adenomatous polyps: quantitative expression of active and proenzyme.
Sim PS; Stephens RW; Fayle DR; Doe WF
Int J Cancer; 1988 Oct; 42(4):483-8. PubMed ID: 3139573
[TBL] [Abstract][Full Text] [Related]
14. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.
De Petro G; Tavian D; Copeta A; Portolani N; Giulini SM; Barlati S
Cancer Res; 1998 May; 58(10):2234-9. PubMed ID: 9605771
[TBL] [Abstract][Full Text] [Related]
15. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer.
Engelhardt M; Drullinsky P; Guillem J; Moore MA
Clin Cancer Res; 1997 Nov; 3(11):1931-41. PubMed ID: 9815582
[TBL] [Abstract][Full Text] [Related]
16. Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
Kohga S; Harvey SR; Weaver RM; Markus G
Cancer Res; 1985 Apr; 45(4):1787-96. PubMed ID: 3884145
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder.
Hasui Y; Suzumiya J; Marutsuka K; Sumiyoshi A; Hashida S; Ishikawa E
Cancer Res; 1989 Feb; 49(4):1067-70. PubMed ID: 2492205
[TBL] [Abstract][Full Text] [Related]
18. Relationship between circulating plasminogen activators and tumor development in mice.
Colombi M; Rebessi L; Boiocchi M; Barlati S
Cancer Res; 1986 Nov; 46(11):5748-53. PubMed ID: 3093069
[TBL] [Abstract][Full Text] [Related]
19. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
[TBL] [Abstract][Full Text] [Related]
20. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro.
Paciucci R; Torà M; Díaz VM; Real FX
Oncogene; 1998 Feb; 16(5):625-33. PubMed ID: 9482108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
